OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUSANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE ORFLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTEDCANDIDEMIA/INVASIVE CANDIDIASIS IN INTENSIVE CARE UNIT PATIENTPOPULATIONS

Pfizer Ltd0 个研究点目标入组 186 人开始时间: 2009年1月13日最近更新: 2012年3月19日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Pfizer Ltd
入组人数: 186

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•Subjects who are willing and able to comply with scheduled visits, treatment plan,
•laboratory tests, and other study procedures.
•Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
•1. Male or female patient =18 years of age.
•2. No contraindications to anidulafungin administration.
•3. Patients with documented Candidemia (at least one blood culture positive for yeast) documented within 96 hours prior to initiation of study treatment.
•Documented invasive candidiasis (histopathologic, microbiologic or cytopathologic examination of a needle aspiration, fluid sample or biopsy specimen from a normally sterile site excluding mucous membranes showing yeast cells) documented within 96 hours prior to initiation of study treatment.
•Patients may be enrolled with a presumptive diagnosis of Candidemia, in which case a culture must be obtained at the screening visit and following completion of written informed consent, as well as daily thereafter in accordance with the protocol. Positive yeast cultures from urine in the absence of clinical symptoms of pyelonephritis; or a positive yeast culture from sputum, obtained by bronchoalveolar lavage or endotracheal aspirate, do not qualify as a positive culture. Candidemia patients who are later found to have no positive bloods culture from any of the three samples taken at screening or within 48 hours after commencing treatment will be considered to not meet entry criteria and will be withdrawn. This will then be considered as an early withdrawal and not as a treatment failure.
•4. ICU patients with a diagnosis of documented candidemia or invasive candidiasis and belonging to one or more of the following specific populations:
•Post-abdominal surgery.
•Elderly > 65 years old.
•Renal insufficiency / failure / hemodialysis.
•Solid tumor.
•Solid-organ (liver, kidney, lung, heart) transplant recipients.
•Hepatic insufficiency.
•Neutropenic including hematology oncology patients.
•5. Presence of one or more of the following signs and symptoms of acute fungal
•infection within 48 hours prior to initiation of study treatment:
•Temperature =38,5°C or a hypothermia, defined as a core temperature <35.0°C.
•Heart rate >90/minute.
•Respiratory frequency>20/minute or PaCO2<32 mm Hg or mechanical
•ventilation.
•White cell >12000/mm3 or <4000/mm3 or immature forms >10%.
•Localized signs and symptoms of inflammation (swelling, heat, erythema or purulence at a site infected with Candida spp.).
•6. Patients having received another anti fungal treatment may be enrolled if in the opinion of the investigator the patient will benefit from the inclusion in the study and:
•The patient has received a systemic antifungal treatment other than an echinocandin, for no more than 48 hours prior to study entry and is showing no sign of improvement.
•The patient has received no more than 1 dose of an echinochandin
•7. APACHE II score <25 at study entry or within the 48 hours prior to study entry.
•8. Patients willing and able to give informed consent, or have a legally authorized
•representative willing to give informed consent on their behalf. The person considered as the legally authorized representative must be in accordance with local law and Ethics Committee policices, including but not limited to a family member.
•9. Expected survival (in the opinion of the investigator) greater than 4 days.
•Are the trial subjects under 18? no
•Number of subjects for this age range:

排除标准

•Subjects presenting with any of the following will not be included in the study:
•1. Patients with poor venous access that would preclude IV drug delivery or multiple blood draws.
•2. Patients with a known hypersensitivity or contraindications the use of anidulafungin, voriconazole or fluconazole or to any of the excipients.
•3. Patient who have participated in a study of an investigational drug or device within four weeks of study entry.
•4. Patient with suspected Candida osteomyelitis, endocarditis, meningitis, endopthalmitis.
•5. Patient with a prosthetic device at a suspected site of infection unless the device was removed at study entry and prior to study drug initiation (hemodialysis shunts [AV fistulae] could remain in situ).
•6. Female patients who are pregnant, lactating, or planning a pregnancy during the course of the study, or who are of child bearing potential and not using an acceptable method of birth control. Female patients should continue contraceptive methods during the study and for at least 28 days after receiving their last treatment.
•7. Other severe or acute chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration that may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial.

研究者

发起方

Pfizer Ltd

相似试验

进行中（未招募）

不适用

EUCTR2007-004854-97-PLPfizer Ltd286

进行中（未招募）

1 期

OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUSANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE ORFLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTEDCANDIDEMIA/INVASIVE CANDIDIASIS IN INTENSIVE CARE UNIT PATIENTPOPULATIONSCANDIDAEMIA/INVASIVE CANDIDIASISMedDRA version: 9.1Level: LLTClassification code 10064954Term: Invasive candidiasis

EUCTR2007-004854-97-FRPfizer Ltd186

进行中（未招募）

不适用

EUCTR2007-004854-97-DEPfizer Ltd286

进行中（未招募）

1 期

EUCTR2007-004854-97-NLPfizer Ltd186

进行中（未招募）

不适用

EUCTR2007-004854-97-BEPfizer Ltd286